Results 41 to 50 of about 23,963 (194)
Sphingolipids as emerging mediators in retina degeneration [PDF]
, 2019 The sphingolipids ceramide (Cer), sphingosine-1-phosphate (S1P), sphingosine (Sph), and ceramide-1-phosphate (C1P) are key signaling molecules that regulate major cellular functions.
Prado Spalm, Facundo Heber +3 more
core +1 more source
Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Epidemiologic studies have reported inconsistent altered cancer risk in individuals with multiple sclerosis (MS). Factors such as immune dysregulation, comorbidities, and disease‐modifying therapies may contribute to this variability.
Asli Buyukkurt +5 more
wiley +1 more source
The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients. [PDF]
, 2016 OBJECTIVE: To assess longitudinally the antiviral immune response of T cells from patients with multiple sclerosis (MS) treated with fingolimod (FTY) vs other disease-modifying treatments (DMTs). METHODS: We assessed cellular immune responses specific to
Canales, M. +6 more
core +1 more source
Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley +1 more source
Neurología, 2014 Resumen: Introducción: Actualmente, existe una ausencia de evaluaciones económicas en el manejo de la esclerosis múltiple remitente-recurrente en segunda línea.
C. Crespo +4 more
doaj +1 more source
Beneficial effects of fingolimod in MS patients with high serum Sema4A levels. [PDF]
PLoS ONE, 2018 We previously demonstrated that patients with multiple sclerosis (MS) of high serum Sema4A levels are resistant to IFN-β therapy. To further elucidate the role of serum Sema4A as a biomarker for therapeutic stratification in MS patients, it is important ...
Toru Koda +13 more
doaj +1 more source
PND20 HEALTHCARE UTILIZATION AND COSTS AMONG AD PATIENTS WITH AND WITHOUT DYSPHAGIA [PDF]
, 2003 Primer pla del bust "Al Dr. Pi i Molist".
Gabriel, S. +3 more
core +1 more source
Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz +8 more
wiley +1 more source
Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
Journal of Investigative Medicine High Impact Case Reports, 2015 A man with relapsing multiple sclerosis, treated with fingolimod 0.5 mg/d for 15 months, developed acute lymphoblastic leukemia and died 4 months after immune ablation and bone marrow allograft, from graft versus host disease.
Stanley Cohan MD, PhD +2 more
doaj +1 more source
Journal of Neuroinflammation, 2022 Background The increasing number of treatments that are now available to manage patients with multiple sclerosis (MS) highlights the need to develop biomarkers that can be used within the framework of individualized medicine.
Celia Camacho-Toledano +13 more
doaj +1 more source